Individualized Octreotide LAR dosing is necessary for patients with NET.
BMI and gender affect blood levels of Octreotide. Dosing needs to be increased for males compared to females and with increasing BMI.
pts enrolled
Height, Weight, and BMI calculated Monthly LAR doses recorded along with trough Octreotide blood levels Pearson's correlation with natural log-tranformed data used to identify factors affecting Octroetide blood levels Octreotide LAR is standard of care for most NET tumors.
Currently, the manufactures suggestion is to start all patients on 20mg/month as a starting dose.
This leads to delays in adequate dosing and symptom relief.
We prospectively studied 82 pts undergoing long-term LAR treatment.
We attempted to understand the relationship between height, weight, BMI, and gender as it pertained to Octreotide dose levels.
We hope to develop a new dosing regimen guided by pt characteristics that would allow for faster titration of LAR in the clinical setting. 
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Females have a higher Octreotide level as compared to men.
As BMI increases, Octreotide levels decrease by 3.4%
Overall, men will require 14.1 mg/month more than women of the same size.
Also, with increasing BMI a dose increase of 1.3mg/month is required to maintain blood levels.
Summary (mean and standard deviation) of plasma octreotide level (pg/ml) by LAR dose (Mg/month) and gender
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